[Neuroprotection therapy of multiple sclerosis with high doses of ethylmethylhydroxypyridine succinate]. / Vozmozhnosti neiroprotektsii pri rasseyannom skleroze: opyt primeneniya vysokikh doz preparata etilmetilgidroksipiridina suktsinat.

AIM: To study the therapeutic action of ethylmethylhydroxypyridine succinate (mexidol) on the neurodegeneration in multiple sclerosis (MS). MATERIAL AND METHODS: Fifty-two MS patients and 24 healthy controls were examined using DTI MRI with tractography. RESULTS AND CONCLUSION: Ethylmethylhydroxypyridine succinate can prevent the progression of neurodegenerative processes in MS. However, further clinical trials are needed to confirm the results obtained in this study.

[The relationship between cognitive impairment and localization of white matter lesions in patients with multiple sclerosis]. / Sviaz' kognitivnykh narushenii s lokalizatsiei ochagov porazheniia belogo veshchestva golovnogo mozga u bol'nykh rasseiannym sklerozom.

Objective. To study a role of parenchymal white matter lesions and lesions of the white matter underlying the cortical grey matter in cognitive impairment in patients with multiple sclerosis (MS). Material and methods. We examined 33 patients with clinically definite RRMS in clinical remission. Cognitive performance was assessed with neuropsychological and psychometric tests. MRI (1.5 tesla) was used to assess volume and localization of focal demyelination in the cerebral cortex. Results. The volume of juxtacortical brain lesions in the white matter had a negative effect on the correct performance on neuropsychological tests. The volume of parenchymal white matter lesions had a negative effect on the speed of task performance. Conclusion. The results suggest that MS patients had multiple cognitive impairments.

Characteristics of neurological and cognitive status in patients with multiple sclerosis in relation to the location and volumes of demyelination foci and the severity of brain atrophy.

A total of 65 patients with clinically significant diagnoses of remitting multiple sclerosis in the stage of remission were studied. Neurological status was investigated with assessment on the FS and EDSS scales, with neuropsychological testing, and MRI scans (1.5 T). The severity of brain atrophy (in terms of the parenchyma volume) and the total volume of foci on T2 images were assessed as proportions of intracerebral volume. The severity of neurological deficit depended on the volume of intratentorial focal lesions and the level of brain atrophy. Cognitive disorders were identified in 89% of patients, and the severity of these was associated with the level of atrophy and the volume of foci on T2 images in the dominant hemisphere.